Clinical Study

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C

Zehui Yan, Ke Fan, Xiaohong Wang, Qing Mao, Guohong Deng, and Yuming Wang

Institute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, China

Correspondence should be addressed to Yuming Wang, wym417@163.com

Received 8 October 2012; Accepted 15 November 2012

Background. The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection.

Patients and Methods. A total of 243 HCV patients treated with different doses of peg-IFN α-2a plus ribavirin were stratified into three groups. End-of-treatment response (ETR) and sustained viral response (SVR) were evaluated for efficacy. Adverse events and laboratory abnormalities were conducted for safety.

Results. ETR and SVR in group I were obtained in 83.9% and 68.9% of the patients, separately, which was similar to groups II (84.1% and 68.3%) and III (81.7% and 66.7%). The received peg-IFN α-2a dose was not the independent factor-related SVR in our population (OR, 1.31; 95% CI, 0.94–1.81; \( P = 0.106 \)). The frequency of no adverse events reported in group III (24.7%) was significantly higher than that in group I (11.5%) and group II (12.7%) (\( P = 0.036 \)).

Conclusions. The peg-IFN α-2a 90 μg/week plus ribavirin is as effective as, and better tolerated than, peg-IFN α-2a standard dose with ribavirin in the treatment of chronic hepatitis C. This low-dose combination achieves high SVR rates and may be cost-saving.

1. Background

The hepatitis C virus (HCV) is a major public health problem affecting 170 million people worldwide, which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease [1, 2]. The currently recommended therapy for patients with chronic hepatitis C is the combination of a pegylated interferon (peg-IFN) alfa plus ribavirin [3]. There are two licensed peg-IFN: peginterferon alfa-2b (peg-IFN α-2b) and peginterferon alfa-2a (peg-IFN α-2a) [4]. The doses of these two forms of peg-IFN differ. According to the updated practice guideline, the optimal dose of peg-IFN α-2b is 1.5 μg/kg/week dosed according to body weight, while peg-IFN α-2a is administered at a fixed dose of 180 μg weekly given subcutaneously together with weight-based ribavirin from 1,000 to 1,200 mg daily for treatment of chronic hepatitis C [3].

The standard therapy regimen with recommended dose peg-IFN in combination with ribavirin is effective in chronic hepatitis patients, resulting in sustained virologic response (SVR) in 40–50% of patients with genotype 1, and around 80% in those infected with genotype 2/3 [3, 5]. However, these peg-IFN-based regimens are accompanied by many adverse effects, including fever, depression, anemia, neutropenia, and thrombocytopenia, and many patients treated require reductions in the dose of one or both agents, or must be discontinued from treatment, because of adverse events [6–8]. The peg-IFN-based combination therapy is also associated with significant cost, which is major limiting factor in initiating treatment and a major reason of treatment withdrawal during the course of therapy, especially for the patients in developing countries [9, 10]. Therefore, it is rational to hypothesize that lower doses of peg-IFN might reduce the cost of therapy, decrease adverse events, and increase the likelihood of completing treatment and achieving an SVR.

Use of lower doses of peg-IFN might be prudent. Some studies have evaluated the effect of reduced dose peg-IFN α-2b (lowered from 1.5 mg/kg body weight to 0.5 mg/kg body weight) plus ribavirin on chronic hepatitis C and found that low-dose peg-IFN α-2b in combination with
ribavirin is as effective as standard high-dose peg-IFN α-2b plus ribavirin on chronic hepatitis C [11–14]. A prospective, randomized, open-label, single-center trial has suggested that peg-IFN α-2a plus ribavirin produced a significantly higher SVR rate than peg-IFN α-2b plus ribavirin in patients with chronic HCV infection [15]. Therefore, it would be worthwhile to study whether the dose of peg-IFN α-2a could be lowered from 180 μg/week to 90 μg/week in combination with standard dose of ribavirin without compromising the efficacy of therapy in chronic hepatitis C patients.

Nevertheless, there is limited data on efficacy of low-dose peg-IFN α-2a (90 μg/week) plus ribavirin on chronic hepatitis C. In a previous study, forty-eight weeks of treatment with 90 μg/week peg-IFN α-2a is safe and produces an SVR in 35–40% of patients with chronic hepatitis C [16]. However, the enrolled patients in that study was individuals with chronic hepatitis C and end-stage renal disease who were being treated with hemodialysis, the treatment regimen in that study was given peg-IFN α-2a monotherapy without ribavirin. In recent years, some patients with chronic hepatitis C have been treated with low-dose peg-IFN α-2a (90 μg/week) plus ribavirin under the guidance of physicians at Southwest hospital. The aims of this study were to assess the efficacy and safety of peg-IFN α-2a at doses of 90 μg/week, 135 μg/week, and 180 μg/week plus ribavirin on chronic hepatitis C patients.

2. Patients and Methods

2.1. Study Participants. This study was a per protocol study and approved by the ethical committee of Southwest Hospital, Chongqing, China. There is prospective informed consent to all participants and prospective baseline characteristics collecting. We identified all consecutive patients with chronic hepatitis C, who were registered and followed up at Southwest Hospital from January 2004 to June 2011. The patients aged 18–65 years who completed the proposed duration of antiviral therapy with peg-IFN α-2a plus ribavirin and had at least 24 weeks followup period after the end of treatment were included. The diagnosis of chronic HCV was made by a persistent or intermittent elevation of alanine aminotransferase (ALT) determined by nucleotide sequencing of the core-envelope 1 region as described in our previous research [17].

According to the different dose of peg-IFN α-2a suggested by local physicians, the patients of current study were stratified into three groups as follows: group I, which was treat with 180 μg subcutaneous weekly dose of peg-IFN α-2a plus ribavirin, group II, which was administered a dose of 135 μg/week of peg-IFN α-2a plus ribavirin, and group III, which received 90 μg per week of peg-IFN α-2a plus ribavirin. The dosage of ribavirin was determined by body weight (800 mg/day in patients <60 kg; 1000 mg/day in patients ≥60 kg). The durations of treatment were 48 wks for patients infected with HCV genotype 1, and 24 wks for patients infected with HCV genotype 2/3/6.

2.2. Efficacy Assessments. Serum HCV RNA levels, routine hematological workup and biological function were determined at baseline, then at weeks 12, 24, and 48 during treatment. Following the completion of treatment, all patients were evaluated at 12 and 24 wk. On each visit during followup, side effects of the therapy were carefully recorded and relevant investigations were performed when necessary. End-of-treatment response (ETR) and SVR were defined, respectively, as a negative qualitative HCV RNA level at the end of treatment and after 24 weeks of untreated followup. Early virological response (EVR) was defined as qualitative HCV RNA negative (complete EVR) or a reduction from baseline HCV RNA level of >2 log10 IU/mL at week 12 (partial EVR). All patients with detectable HCV RNA at week 24 stopped treatment and were classified as nonresponders. Virological relapse was defined as reversion to HCV RNA-positive status in a patient who had an undetectable HCV RNA level (<50 IU/mL) at the end of treatment. The primary efficacy end point of the study was SVR.

2.3. Safety Assessments. Safety assessments including adverse events, vital signs, and laboratory tests were conducted throughout treatment and followup. Patients were monitored at each outpatient visit for adverse events and laboratory abnormalities. Information on possible adverse events was obtained by questioning the patients in a structured way about specific, commonly observed, and expected side effects of the study medication, such as flu-like symptoms, fatigue, nausea/vomiting/diarrhea, dizziness, depression, and hair loss. In addition, spontaneously reported adverse events were recorded.

2.4. Statistical Analysis. Statistical analysis was performed using SPSS software (version 9.0; SPSS Inc, Chicago, IL). Quantitative variables were expressed as mean ± standard deviation and were compared by the Mann-Whitney rank sum test. Frequencies were calculated for categorical variables and were compared by the χ² test. Multivariable logistic stepwise regression analysis was used to explore the independent effect of the treatment and the baseline factors (age, body weight sex, presence of cirrhosis, ALT level, HCV RNA level, HCV genotype) on the likelihood of achieving SVR, with the difference between groups reported with 95% confidence intervals (CIs). A 2-sided P value less than 0.05 was considered significant.
3. Results

3.1. Characteristics of the Patient. Between January 2004 and June 2011, a total of 243 patients treated with peg-IFN α-2a plus ribavirin were included in this analysis. The age of the total 243 patients ranged from 19 to 65 years with a mean age (±SD) of 39.8 ± 9.9 years. Of them, 145 patients (59.7%) were males and 98 patients (40.3%) were females, included 130 patients (53.5%) with HCV-1b infection, 20 patients (8.2%) with HCV-2a infection, 60 patients (24.7%) with HCV-3 infection, and 33 patients (13.6%) with HCV-6a infection. Of them, 66 individuals (27.2%) had evidence of obvious cirrhosis or extensive fibrosis at the time of beginning therapy. The pretreatment ALT levels were 97.5 ± 124.6 IU/L, and 96 patients (39.5%) had elevated ALT ≥2 times the upper limit of normal (ULN). The pretreatment HCV RNA levels of all patients ranged from 1 × 10^2 to 1.7 × 10^7 IU/mL with median 6.4 × 10^5 IU/mL, and the pretreatment HCV RNA levels of 125 patients (51.4%) were higher than 6.0 × 10^5 IU/mL.

There were 87 patients treated with peg-IFN α-2a 180 μg/week plus ribavirin in group I, while 65 cases treated with peg-IFN α-2a 130 μg/week plus ribavirin in group II, and 93 cases treated with peg-IFN α-2a 90 μg/week plus ribavirin in group III. The baseline characteristics of the three groups are shown in Table 1. The major factors of demography and anthropometry (age, gender, and body weight) and clinical basic characteristics (cirrhosis, the pretreatment ALT, and HCV RNA levels) of the three treatment groups were similar (all P > 0.05).

3.2. Efficacy: Table 2 compares the virological response during treatment and at the end of followup to peg-IFN α-2a plus ribavirin therapy among patients with different peg-IFN α-2a dose groups. Except for complete EVR, differences in the rate of EVR, ETR, and SCR among patients treated with three different doses peg-IFN α-2a plus ribavirin were not statistically significant (P > 0.05).

Among the 243 patients, only 172 patients were tested HCV RNA level at week 12 of treatment, among these 172 patients, 149 patients achieved EVR. The rate of RVR in group I (91.5%) was higher than that in group II (88.2%) and even higher than that in group I (82.3%), although the difference was not statistically significant (P = 0.197). The majority of patients obtained a complete EVR, while the number of those who obtained a partial EVR was only 11.0%, with no difference among the three groups. However, for the patients who achieved EVR, the rate of complete EVR in group III (64.5%) was significantly lower than that in group I (83.1%) and that in group II (80.4%) (P = 0.038).

Overall, ETR was seen in 202/243 patients (83.1%). The rates of ETR of three groups were 83.9% for group I, 84.1% for group II, and 81.7% for group III, respectively. There were no significantly differences of the ETR rates for the three groups (P = 0.899). At the end of 24 weeks followup, a SVR was obtained in 165 patients (67.9%), including 60 of 87 (68.9%) in group I, 43 of 63 (68.3%) in group II, and 62 of 93 (66.7%) in group III. There was no significant difference of SVR among the three independent groups with different peg-IFN α-2a dose (P = 0.945). The total number of patients who experienced a relapse during followup was 37 of 243 (15.2%), including 13 of 87 (14.9%) in group I versus 10 of 63 (15.9%) in group II and 14 of 93 (15.1%) in group III.

As reported in Table 2, 73 of 130 patients (56.2%) infected with genotype 1 achieved a SVR, including 29 of 50 (58.0%) in group I, 18 of 32 (56.3%) in group II, and 26 of 48 (54.2%) in group III (P = 0.877). A total of 66 of 80 patients with genotype 2 or 3 obtained a SVR. The SVR rates of patients infected with genotype 2 or 3 for the three groups with different peg-IFN α-2a dose were similar. The rate of SVR of patients infected with genotype 6 in group I (83.3%) was higher than that in group II (80.0%) and even higher than that in group I (72.7%), but the difference was not statistically significant (P = 0.819). Among patients without cirrhosis, an SVR was achieved by 130 of 177 patients (73.4%). The SVR rates of patients without cirrhosis for the three groups with different peg-IFN α-2a dose were similar. The rate of SVR of patients with cirrhosis in group I (47.5%) was lower than that in group II (55.6%) and even higher than that in group I (58.1%), although the difference was not statistically significant (P = 0.834).

An SVR was obtained in 87 of 118 patients (73.7%) with a baseline HCV RNA level <600,000 IU/mL, including 29 of 40 (72.5%) in group I, 20 of 28 (71.4%) in group II, and 38 of 50 (76.6%) in group III. No significantly differences of the ETR rates were found among the three groups (P = 0.887). In 125 patients with higher baseline HCV RNA level (≥600,000 IU/mL), 78 cases achieved SVR (62.4%), including 31 of 47 (66.0%) in group I, 23 of 35 (65.7%) in group II, and 24 of 43 (55.8%) in group III.

To further analyze the influence of low-dose peg-IFN α-2a treat regimen to SVR, we also conducted multivariate stepwise analysis included in the model the following preselected variables: peg-IFN α-2a dose of treatment, gender, age, HCV genotype, absence of cirrhosis, and HCV RNA level. As Table 3 showed, according to multivariate stepwise analysis, SVR was significantly associated with HCV genotype 2/3/6 (OR, 3.87; 95% CI, 2.16–5.89; P = 0.0002), absence of cirrhosis (OR, 2.47; 95% CI, 1.36–3.67; P = 0.008), and lower (<600 IU/mL × 10^3) HCV RNA level (OR, 1.68; 95% CI, 1.12–2.57; P = 0.038). However, the peg-IFN α-2a dose of treatment was not the independent factor related SVR in our population (OR, 1.31; 95% CI, 0.94–1.81; P = 0.106).

3.3. Safety. Treatment was generally well tolerated with no unexpected safety concerns. No serious adverse events (death or any kind of life-threatening event) were reported. As Table 4 showed, a total of 47 patients had a hemoglobin concentration <80 g/L, 6 patients (2.5%) had a neutrophil count <0.75 × 10^9/L, and 9 patients (3.7%) had a platelet count <50 × 10^9/L. There was no statistically significant difference for the incidence of the hematological toxicity among the three different peg-IFN α-2a dose groups (P > 0.05). However, only one patient of group III (1.1%) occurred the thyroid dysfunction during the treatment, while 9 patients of group I (10.2%) and 5 patients of group II (7.9%) occurred the thyroid dysfunction (P = 0.028).
### Table 1: The baseline characteristics of the patients.

| Characteristics                        | Overall (n = 243) | Group I: peg-IFN α-2a 180 μg/week plus ribavirin (n = 87) | Group II: peg-IFN α-2a 135 μg/week plus ribavirin (n = 63) | Group III: peg-IFN α-2a 90 μg/week plus ribavirin (n = 93) |
|----------------------------------------|-------------------|----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|
| Demography and anthropometry           |                   |                                                          |                                                           |                                                          |
| Age (y), Mean (SD)                     | 39.8 (9.9)        | 38.5 (8.8)                                               | 38.7 (9.7)                                                | 41.7 (10.7)                                               |
| Sex, male/female (% male)              | 145/98 (59.7)     | 53/34 (60.9)                                             | 38/25 (60.3)                                             | 54/39 (58.1)                                             |
| Mean (SD) body wt (kg)                 | 59.2 (12.4)       | 62.5 (10.8)                                              | 61.3 (10.4)                                              | 57.3 (10.6)                                              |
| Genotype, n (%)                        |                   |                                                          |                                                           |                                                          |
| 1                                      | 130 (53.5)        | 50 (52.3)                                                | 32 (50.8)                                                | 48 (51.6)                                                |
| 2                                      | 20 (8.2%)         | 4 (4.6)                                                  | 6 (9.4)                                                  | 10 (10.8)                                                |
| 3                                      | 60 (24.7)         | 21 (24.1)                                                | 15 (23.8)                                                | 24 (25.8)                                                |
| 6                                      | 33 (13.6)         | 12 (13.8)                                                | 10 (15.9)                                                | 11 (11.8)                                                |
| Diagnosis, n (%)                       |                   |                                                          |                                                           |                                                          |
| Chronic hepatitis                      | 177 (72.8)        | 66 (75.9)                                                | 45 (71.4)                                                | 66 (71.0)                                                |
| Cirrhosis                              | 66 (27.2)         | 21 (24.1)                                                | 18 (28.6)                                                | 27 (29.0)                                                |
| ALT                                    |                   |                                                          |                                                           |                                                          |
| Mean (SD) ALT level, IU / L,           | 97.5 (124.6)      | 112.1 (164.3)                                            | 104.2 (178.1)                                            | 92.1 (152.7)                                             |
| No. (%) with <2 ULN                    | 147 (60.5)        | 56 (64.4)                                                | 39 (61.9)                                                | 52 (55.9)                                                |
| No. (%) with ≥2 ULN                    | 96 (39.5)         | 31 (35.6)                                                | 24 (38.1)                                                | 41 (44.1)                                                |
| HCV RNA level                          |                   |                                                          |                                                           |                                                          |
| Median (range) HCV RNA, IU/mL × 10^3   | 636 (0.10–17650)  | 678 (0.50–17650)                                        | 625 (0.20–14200)                                        | 512 (0.10–16250)                                        |
| No. (%) with <600 IU/mL × 10^3         | 118 (48.6)        | 40 (46.0)                                                | 28 (44.4)                                                | 50 (53.8)                                                |
| No. (%) with ≥600 IU/mL × 10^3         | 125 (51.4)        | 47 (54.0)                                                | 35 (55.6)                                                | 43 (46.2)                                                |

Notes. SD: standard deviation, ALT: serum alanine aminotransferase levels; ULN: upper limit of normal.

### Table 2: Virological response during treatment and at the end of followup.

| Virological Response | Overall (n = 243) | Group I: peg-IFN α-2a 180 μg/week plus ribavirin (n = 87) | Group II: peg-IFN α-2a 135 μg/week plus ribavirin (n = 63) | Group III: peg-IFN α-2a 90 μg/week plus ribavirin (n = 93) | P value |
|----------------------|-------------------|----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|---------|
| EVR, no./total (%)   | 149/172 (86.7)    | 54/59 (91.5)                                             | 45/51 (88.2)                                             | 50/62 (82.3)                                             | 0.197   |
| Complete             | 130/172 (75.6)    | 49/59 (83.1)                                             | 41/51 (80.4)                                             | 40/62 (64.5)                                             | 0.038   |
| Partial              | 19/172 (11.0)     | 5/59 (8.5)                                              | 4/51 (7.8)                                              | 10/62 (16.1)                                             | 0.278   |
| ETR, no./total (%)   | 202/243 (83.1)    | 73/87 (83.9)                                             | 53/63 (84.1)                                            | 76/93 (81.7)                                             | 0.899   |
| SVR, no./total (%)   | 165/243 (67.9)    | 60/87 (68.9)                                             | 43/63 (68.3)                                            | 62/93 (66.7)                                             | 0.945   |
| 1b                   | 73/130 (56.2)     | 29/50 (58.0)                                             | 18/32 (56.3)                                            | 26/48 (54.2)                                             | 0.877   |
| 2/3                  | 66/80 (82.5)      | 21/25 (84.0)                                             | 17/21 (81.0)                                            | 28/34 (82.4)                                             | 0.964   |
| 6a                   | 26/33 (78.8)      | 10/12 (83.3)                                             | 8/10 (80%)                                              | 8/11 (72.7)                                              | 0.819   |
| SVR by diagnosis, no./total (%)       |                   |                                                          |                                                           |                                                          |         |
| Chronic hepatitis     | 130/177 (73.4)    | 50/66 (75.8)                                             | 33/45 (73.3)                                             | 47/66 (71.2)                                             | 0.839   |
| Cirrhosis             | 35/66 (53.0)      | 10/21 (47.6)                                             | 10/18 (55.6)                                            | 15/27 (58.1)                                             | 0.834   |
| SVR by baseline HCV RNA, no./total (%) |                   |                                                          |                                                           |                                                          |         |
| <600,000 IU/mL        | 87/118 (73.7)     | 29/40 (72.5)                                             | 20/28 (71.4)                                            | 38/50 (76.0)                                             | 0.887   |
| ≥600,000 IU/mL        | 78/125 (62.4)     | 31/47 (66.0)                                             | 23/35 (65.7)                                            | 24/43 (55.8)                                             | 0.545   |

Notes. * Among the 243 patients who completed the proposed duration of antiviral therapy with peg-IFN α-2a plus ribavirin and had at least 24 weeks followup period after the end of treatment, only 172 patients were tested HCV RNA level at week 12 of treatment, among these 172 patients, 149 patients achieved RVR. *P* value was given by 2 × 3 chi-square test comparing the three different peg-IFN α-2a dose groups. EVR: early virological response. ETR: end-of-treatment response. SVR: sustained virologic response.
Table 3: Results of multivariate stepwise analysis for associated factor to SVR.

| Factor                  | Category        | Patients with SVR, no./total (%) | Patients without SVR, no./total (%) | P value | 95% CI       |
|-------------------------|-----------------|----------------------------------|-------------------------------------|---------|-------------|
| Gender                  | Male            | 98/145 (67.6)                    | 47/145 (33.4)                      | 0.114   | 1.23 (0.91–2.03) |
| Age                     | <40 years       | 93/132 (70.5)                    | 39/132 (29.5)                      | 0.093   | 1.02 (0.83–1.72) |
| HCV genotype            | Genotype 1      | 73/130 (56.2)                    | 57/130 (43.8)                      | 0.0002  | 3.87 (2.16–5.89) |
| Absence of cirrhosis    | With            | 35/66 (53.0)                     | 31/66 (47.0)                       | 0.008   | 2.47 (1.36–3.67) |
| HCV RNA level           | <600 IU/mL × 10^4 | 87/118 (73.7)                  | 31/118 (26.3)                      | 0.038   | 1.68 (1.12–2.57) |
| Peg-IFN α-2a dose       | 90 μg/week      | 62/93 (66.7)                     | 31/93 (33.3)                       | 0.106   | 1.31 (0.94–1.81) |

Table 4 also showed the types and frequencies of common adverse events (>10%). Overall, 41 of 243 patients (16.9%) reported no adverse events, including 10 of 87 (11.5%) in group I, 8 of 63 (12.7%) in group II, and 23 of 93 (24.7%) in group III. The frequencies of common adverse events were similar between the group I and group II (all P > 0.05), although the frequencies in group III were slightly lower than that in group I. There was significant difference of adverse events frequencies between patients with peg-IFN α-2a 90 μg/week plus ribavirin treatment than those with peg-IFN α-2a 180 μg/week plus ribavirin treatment (P = 0.022). Furthermore, the frequencies of the top three common adverse events, fatigue, fever, and headache in group III were also significant lower than that in group I.

4. Discussion

The current standard of care for HCV infection, peg-IFN alfa plus ribavirin is costly and has a significant adverse event profile. It has been reported that reduced doses of ribavirin have been found to be effective and safe in the treatment of genotype 2 or 3 HCV infections [18]. It also has been found that 135 μg peg-IFN α-2a weekly combined with RBV dosed daily according to body weight was sufficient for treatment of genotype 2 and 3 chronic hepatitis C [19], and 135 μg peg-IFN α-2a weekly monotherapy also effective in genotype 1 patients with cirrhosis [20]. Nevertheless, there is a paucity data on efficacy and safety of low-dose peg-IFN α-2a (90 μg/week) plus ribavirin on chronic hepatitis C. To our knowledge, our observational study is the first study to compare the efficacy and safety/tolerability of the combination therapy of low-dose peg-IFN α-2a (90 μg/week) plus ribavirin in naive patients with chronic HCV from China.

The main conclusion of our study can be summarized in two points. First, we observed that the rates of SVR and ETR in patients with treatment of peg-IFN α-2a 90 μg/week plus ribavirin were all similar to those in patients with treatment of peg-IFN α-2a 180 μg/week plus ribavirin. Second, current study suggested that the peg-IFN α-2a 90 μg/week plus ribavirin was better tolerated than the peg-IFN α-2a 180 μg/week and 135 μg/week plus ribavirin, based on the fact that adverse events were less frequently reported with the lower peg-IFN α-2a dose. Although the difference in rates of complete EVR between patients with treatment of peg-IFN α-2a 90 μg/week plus ribavirin and those with treatment of peg-IFN α-2a 180 μg/week plus ribavirin was statistically significant, we think there are two possible reasons for this. (i) A total 71 of 243 patients (29.2%) missed the data of HCV RNA level at week 12 during treatment, which would cause false statistically significant about EVR. (ii) Similar to the peg-IFN α-2b [21], peg-IFN α-2a also dose-dependently correlated with complete EVR. However, SVR, representing the primary efficacy endpoint, did not significantly differ between the peg-IFN α-2a higher and lower dose. Furthermore, the peg-IFN α-2a dose of treatment was not the independent factor related SVR according to multivariate stepwise analysis.
A number of host and viral factors influence SVR rates in patients with chronic hepatitis C [22, 23]. The most important factors are the genotype of the infecting HCV strain and baseline HCV RNA level. Patient age, gender, race, body mass index, and the extent of hepatic fibrosis all influence SVR rates. Patients with the IL28B rs12979860 C/C genotype have significantly higher on-treatment response rates than patients carrying the T-allele [24]. The ribavirin genotype have significantly higher on-treatment response rates than patients carrying the T-allele [24]. The ribavirin daily dose of 10 mg/kg, which, by means of a retrospective subgroup analysis of Manns’ phase III trial, has previously been suggested to be the most efficacious [6]. Thus, it seems highly unlikely that the results of our study were affected by the flat ribavirin dose used. Additionally, in our present study, SVR in our whole cohort was significantly associated with HCV genotype 2/3/6, absence of cirrhosis, and lower HCV RNA level (<600 IU/mL × 10³). However, the major factors of demography and anthropometry (age, gender, and body weight) and clinical basic characteristics (cirrhosis, the pretreatment ALT, and HCV RNA levels) of the three treatment groups with different peg-IFN α-2a dose were similar. Thus, it also seems unlikely that the results of our study were affected by the different baseline characteristics of three groups.

We think there are some other possible reasons that may be contributed to the similar effect of low-dose peg-IFN α-2a plus ribavirin on chronic hepatitis C. First, the body weight and body mass index were lower in our Chinese population. According to the results from China health and nutrition surveys [25]. The mean body weight of Chinese adults is 55.9 kg with mean body mass index 21.7 kg/m². This lower body weight of patients in the present study may be in favor of achieving a higher SVR even when treatments with low-dose peg-IFN α-2a plus ribavirin. Second, the high frequency of the rs12979860 genotype CC in Chinese population also may explain why the SVR rate of patients treated with low-dose peg-IFN α-2a plus ribavirin is similar with that of patients treated with high-dose peg-IFN α-2a, and higher than that of the average global population. The rs12979860 genotype CC, which was associated with SVR, was the primary genotype (nearly 90%), and genotypes CT and TT were found in only about 10% individual within Chinese population [26, 27]. Third, adherence to peg-IFN regimen was reported to be an important factor for SVR [28]. A study by Sood et al. [11] also revealed that a low-dose peg-IFN regimen was associated with fewer grade 3 and 4 side-effects in neutrophil and platelet counts, a potential benefit that does not manifest when patients are treated with the standard high dose regimen. These observations are likely to improve the compliance of the patients. Reduced doses of peg-IFN may decrease cost and reduce the frequency and severity of side-effects, then increase tolerability and efficacy.

In conclusion, our study is the first to indicate that the peg-IFN α-2a 90 μg/week dose is as effective as peg-IFN α-2a 180 μg/week when combined with ribavirin in the treatment of chronic hepatitis C, but suggesting a better tolerability of the peg-IFN α-2a 90 μg/week plus ribavirin. However, as a per protocol analysis performed only in one centre, these findings need to be confirmed in larger, preferably double-blind trials, such as for example the study individualized dosing efficacy versus flat dosing to assess optimal peg-IFN α-2a therapy.

**Conflict of Interests**

The authors have no financial disclosure to report. They declare that they have no conflict of interests.

---

**Table 4: Adverse clinical and laboratory reported during treatment and followup.**

| Adverse Events                         | Overall (n = 243) | Group I: peg-IFN α-2a 180 μg/week plus ribavirin (n = 87) | Group II: peg-IFN α-2a 135 μg/week plus ribavirin (n = 63) | Group III: peg-IFN α-2a 90 μg/week plus ribavirin (n = 93) | P value |
|----------------------------------------|------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------|
| Laboratory abnormalities               |                  |                                                          |                                                          |                                                          |         |
| Hemoglobin < 80 g/L                    | 47 (19.3)        | 18 (20.7)                                                | 12 (19.1)                                                | 17 (18.3)                                                | 0.918   |
| Neutrophils < 0.75 × 10⁹/L            | 6 (2.5)          | 3 (3.4)                                                  | 2 (2.3)                                                  | 1 (1.1)                                                  | 0.541   |
| Platelets < 50 × 10⁹/L                | 9 (3.7)          | 4 (4.6)                                                  | 3 (4.7)                                                  | 2 (2.2)                                                  | 0.600   |
| Thyroid dysfunction                    | 15 (6.2)         | 9 (10.2)                                                 | 5 (7.9)                                                  | 1 (1.1)                                                  | 0.028   |
| No adverse events, n (%)              | 41 (16.9)        | 10 (11.5)                                                | 8 (12.7)                                                 | 23 (24.7)                                                | 0.036   |
| Common adverse events (>10%)          |                  |                                                          |                                                          |                                                          |         |
| Fatigue                                | 154 (63.4)       | 65 (74.7)                                                | 38 (60.3)                                                | 51 (54.8)                                                | 0.018   |
| Fever                                  | 134 (55.1)       | 55 (63.2)                                                | 34 (54.0)                                                | 45 (48.4)                                                | 0.132   |
| Headache                               | 67 (27.6)        | 31 (35.6)                                                | 16 (25.4)                                                | 20 (21.5)                                                | 0.096   |
| Dermatitis or Pruritus                 | 46 (18.9)        | 20 (22.9)                                                | 11 (17.5)                                                | 15 (16.1)                                                | 0.473   |
| Nausea                                 | 34 (13.9)        | 15 (17.2)                                                | 9 (14.3)                                                 | 10 (10.8)                                                | 0.454   |
| Arthralgia or Myalgia                  | 30 (12.3)        | 12 (13.8)                                                | 9 (14.3)                                                 | 9 (9.7)                                                  | 0.607   |
| Irritability or Depression             | 27 (11.1)        | 11 (12.6)                                                | 8 (12.7)                                                 | 8 (8.6)                                                  | 0.619   |
| Insomnia                               | 25 (10.3)        | 10 (11.5)                                                | 8 (12.7)                                                 | 7 (7.5)                                                  | 0.522   |

Notes. All values are expressed as n (%). P value was given by 2 × 3 chi-square test comparing the three different peg-IFN α-2a dose groups.
Authors’ Contribution

Z. Yan and Y. Wang designed the study and were responsible for the overall study management. Z. Yan, K. Fan and G. Deng did the analysis. Z. Yan, X. Wang, and Q. Mao prepared the paper. All authors contributed to the final version of the paper.

Acknowledgments

This work was supported in part by the State Key Project Specialized for Infectious Diseases (2012ZX10002-004). The funding sources had no role in study design, collection, analysis, or interpretation of data, the writing of the paper, or the decision to submit it for publication.

References

[1] C. W. Shepard, L. Finelli, and M. J. Alter, “Global epidemiology of hepatitis C virus infection,” The Lancet Infectious Diseases, vol. 5, no. 9, pp. 558–567, 2005.

[2] F. Negro and A. Alberti, “The global health burden of hepatitis C virus infection,” Liver International, vol. 31, supplement 2, pp. 1–3, 2011.

[3] M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009.

[4] S. Zeuzem, C. Welsch, and E. Herrmann, “Pharmacokinetics of peginterferons,” Seminars in Liver Disease, vol. 23, supplement 1, pp. 23–28, 2003.

[5] J. G. McHutchison, E. J. Lawitz, M. L. Shiffman et al., “Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,” The New England Journal of Medicine, vol. 361, no. 6, pp. 580–593, 2009.

[6] M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001.

[7] E. M. Sokal, A. Bourgois, X. Stéphenne et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents,” Journal of Hepatology, vol. 52, no. 6, pp. 827–831, 2010.

[8] M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002.

[9] M. Solomon, M. Bonafe and K. Pan et al., “Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients,” Digestive Diseases and Sciences, vol. 56, no. 10, pp. 3024–3031, 2011.

[10] J. S. McCombs, Y. Yuan, J. Shin, and S. Saab, “Economic burden associated with patients diagnosed with hepatitis C,” Clinical Therapeutics, vol. 33, no. 9, pp. 1268–1280, 2011.

[11] A. Sood, V. Midha, S. Hissar et al., “Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience,” Journal of Gastroenterology and Hepatology, vol. 23, no. 2, pp. 203–207, 2008.

[12] B. Meyer-Wyss, P. Rich, H. Egger et al., “Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 μg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis,” Journal of Viral Hepatitis, vol. 13, no. 7, pp. 457–465, 2006.

[13] R. Gupta, C. H. Ramakrishna, S. Lakhtakia, M. Tandan, R. Banerjee, and D. N. Reddy, “Efficacy of low dose peginterferon alfa-2b with ribavirin on chronic hepatitis C,” World Journal of Gastroenterology, vol. 12, no. 34, pp. 5554–5556, 2006.

[14] A. Abergel, C. Hezode, V. Leroy et al., “Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alfa-2b,” Journal of Viral Hepatitis, vol. 13, no. 12, pp. 811–820, 2006.

[15] A. Ascione, M. De Luca, M. T. Tartaglione et al., “Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection,” Gastroenterology, vol. 138, no. 1, pp. 116–122, 2010.

[16] M. Peck-Radosavljevic, J. Boletis, F. Besik et al., “Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease,” Clinical Gastroenterology and Hepatology, vol. 9, no. 3, pp. 242–248, 2011.

[17] Z. Yan, K. Fan, Y. Wang, Y. Fan, Z. Tan, and G. Deng, “Changing pattern of clinical epidemiology on hepatitis C virus infection in Southwest China,” Hepatitis Monthly, vol. 12, no. 3, pp. 196–204, 2012.

[18] S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004.

[19] O. Weiland, A. Hollander, L. Mattsson et al., “Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin,” Journal of Viral Hepatitis, vol. 15, no. 9, pp. 641–645, 2008.

[20] S. Zeuzem, S. V. Feinman, J. Rasenack et al., “Peginterferon alfa-2a in patients with chronic hepatitis C,” The New England Journal of Medicine, vol. 343, no. 23, pp. 1666–1672, 2000.

[21] T. Oze, N. Hiramatsu, T. Yakushijin et al., “Pegylated interferon-alpha2b (Peg-IFN a-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN a-2b plus ribavirin,” Journal of Viral Hepatitis, vol. 16, no. 8, pp. 578–585, 2009.

[22] S. Zeuzem, “Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?” Annals of Internal Medicine, vol. 140, no. 5, pp. 370–381, 2004.

[23] P. Ferenci, “Optimal treatment duration for patients with HCV genotype 1 infection,” Journal of Viral Hepatitis, vol. 19, supplement 1, pp. 7–13, 2012.

[24] D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009.

[25] B. M. Popkin, S. Paeratakul, K. Ge, and Z. Fengying, “Body weight patterns among the Chinese: results from the 1989 and 1991 China health and nutrition surveys,” American Journal of Public Health, vol. 85, no. 5, pp. 690–694, 1995.

[26] X. W. Liao, Y. Ling, X. H. Li et al., “Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population,” Antiviral Therapy, vol. 16, no. 2, pp. 141–147, 2011.
[27] M. L. Yu, C. F. Huang, J. F. Huang et al., “Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients,” *Hepatology*, vol. 53, no. 1, pp. 7–13, 2011.

[28] M. P. Manns, H. Wedemeyer, and M. Cornberg, “Treating viral hepatitis C: efficacy, side effects, and complications,” *Gut*, vol. 55, no. 9, pp. 1350–1359, 2006.